Graft-versus-host disease and relapse/rejection-free survival after allogeneic transplantation for idiopathic severe aplastic anemia: a comprehensive analysis from the SAAWP of the EBMT.

Abstract

Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for severe idiopathic aplastic anemia (SAA) has improved in recent years, approaching 75% at 5 years. However, an SAA-adapted composite endpoint, graft-versus-host disease (GvHD) and relapse/rejection-free survival (GRFS), may more accurately assess patient outcomes beyond survival. We analyzed GRFS to identify risk factors and specific causes of GRFS failure. Our retrospective analysis from the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation included 479 patients with idiopathic SAA who underwent allo-HSCT in two conventional situations: i) upfront allo-HSCT from a matched related donor (MRD) (upfront cohort), and ii) allo-HSCT for relapsed or refractory SAA (rel/ref cohort). Relevant events for GRFS calculation included graft failure, grade 3-4 acute GvHD, extensive chronic GvHD, and death. In the upfront cohort (n=209), 5-year GRFS was 77%. Late allo-HSCT (i.e., >6 months after SAA diagnosis) was the main poor prognostic factor, specifically increasing the risk of death as the cause of GRFS failure (hazard ratio [HR]=4.08; 95% confidence interval [CI]: 1.41-11.83; P=0.010). In the rel/ref cohort (n=270), 5-year GRFS was 61%. Age was the main factor significantly increasing the risk of death (HR=1.04; 95% CI: 1.02-1.06; P<0.001), acute GvHD (HR=1.03; 95% CI: 1.00-1.07; P=0.041), and chronic GvHD (HR=1.04; 95% CI: 1.01-1.08; P=0.032) as the cause of GRFS failure. GRFS after upfront MRD allo-HSCT was very good, notably with early allo-HSCT, confirming that younger patients with an MRD should be transplanted immediately. GRFS was worse in cases of salvage allo-HSCT, most notably in older patients, questioning the utility of allo-HSCT earlier in the disease course.

• Authors: Raynier Devillier, Dirk-Jan Eikema, Carlo Dufour, Mahmoud Aljurf, Depei Wu, Alexei Maschan, Alexander Kulagin, Constantijn J M Halkes, Matthew Collin, John Snowden, Cécile Renard, Arnold Ganser, Karl-Walter Sykora, Brenda E Gibson, Johan Maertens, Maija Itäla-Remes, Paola Corti, Jan Cornelissen, Martin Bornhäuser, Mercedes Colorado Araujo, Hakan Ozdogu, Antonio Risitano, Gerard Socie, Regis Peffault De Latour
• Journal: Haematologica (Haematologica) Vol. 108 Issue 9 Pg. 2305-2315 (09 01 2023) ISSN: 1592-8721 [Electronic] Italy
• PMID: 36951165 (Publication Type: Journal Article)

Topics

• Humans
• Aged
• Anemia, Aplastic (complications)
• Retrospective Studies
• Disease-Free Survival
• Graft vs Host Disease (diagnosis, etiology)
• Transplantation, Homologous (adverse effects)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Bronchiolitis Obliterans Syndrome